OCGN insider trading
NasdaqCM HealthcareOcugen, Inc.: insider trade history from SEC Form 4 filings.
About Ocugen, Inc.
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Company website: www.ocugen.com
OCGN insider activity at a glance
FilingIQ tracks 172 insider transactions for OCGN in filings since Oct 4, 2019. The most recent transaction is dated Sep 9, 2026.
Across the full history, 31 open-market purchases
and 66 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on OCGN insider trades is 51.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest OCGN Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for OCGN?
- FilingIQ tracks 172 Form 4 insider transactions for OCGN (Ocugen, Inc.), covering filings from Oct 4, 2019 onwards. 2 of those are dated within the last 90 days.
- Are OCGN insiders net buyers or net sellers?
- Across the full Form 4 history for OCGN, 31 transactions (18%) were open-market purchases and 66 (38%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does OCGN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is OCGN in?
- Ocugen, Inc. (OCGN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $586.94M.
Methodology & sources
Every OCGN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.